logo
logo

Carlsmed raised $52.5M in a Series C funding round co-led by B Capital and U.S. Venture Partners to advance the aprevo® personalized spine surgery platform.

Mar 18, 2024•over 1 year ago

Amount Raised

$52.5 Million

Round Type

series c

CarlsbadBiotechnology

Investors

U.S. Venture PartnersB Capital

Description

Carlsmed announced a $52.5 million Series C funding round co-led by B Capital and U.S. Venture Partners. The funding will be used to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, set to launch in 2025.

Company Information

Company

Carlsmed

Location

1800 Aston Avenue, Suite 100

Carlsbad, California, United States

About

Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery. The company’s aprevo® devices are designed to improve the standard of care for surgical treatment of patients with adult spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices for each patient. The Carlsmed® aprevo® devices are FDA cleared and have been granted FDA Breakthrough Designation, an industry first for any implanted device, and are commercially available in the U.S.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People